Page 4 - Veronica Eames News Today

Investegate announcements from Providence Therapeutics, Providence Therapeutics Appoints Judyanna Yu as Chief Financial Officer

CALGARY, Alberta, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, announces

RALEIGH, NC / ACCESSWIRE / October 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced

RALEIGH, NC / ACCESSWIRE / September 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced

Press release content from Accesswire. The AP news staff was not involved in its creation.

RALEIGH, NC / ACCESSWIRE / July 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced

9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome - Initial Draw of $20 Million to Support Funding Phase 3 Development... | June 30, 2022

Additional analyses to determine if a subgroup of patients and/or symptoms may have been responsive to treatmentCompany remains on track to deliver vurolenatide Phase 2 short bowel syndrome results by

9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation -Additional analyses to... | June 21, 2022

13.06.2022 - RALEIGH, NC / ACCESSWIRE / June 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the Companys participation in the 2022 BIO ...